PF-08654696 / Pfizer - LARVOL DELTA

Additional key pipeline programs: Combination and prodrug candidates continue to advance, with multiple clinical milestones expected in late 2025 and early 2026 (Metsera Press Release) - "Preliminary data from co-administration of MET-034, an ultra-long acting GIP RA (Metsera’s third HALO-engineered peptide in clinical testing), with MET-097i are expected in late 2025; IND-enabling studies progressing for MET-815, a prodrug of MET-097i with potential for quarterly maintenance dosing; clinical trial initiation planned for year-end 2025 or early 2026."

New trial • Preclinical • Obesity

Based on positive topline data, Metsera is rapidly advancing MET-233i as a monotherapy and in combination with MET-097i: - "An ongoing monotherapy trial evaluates 12 weekly doses of MET-233i with dose titration, followed by an exposure-matched monthly dose at week 13. Topline data from this trial are expected in late 2025; Metsera has extended an ongoing co-administration trial of MET-233i and MET-097i to twelve weeks, with topline data expected by year-end 2025 or early 2026; The Company also expects to report topline clinical data from its ultra-long acting GIP receptor agonist, MET-034i, in combination with MET-097i, in late 2025. We anticipate that MET-034i will be the third peptide engineered with Metsera’s HALO™ platform to enter clinical testing."

New trial • P1 data • P2b data • Pipeline update • Obesity